Melanoma: smart therapeutic strategies in immuno-oncology.

Nature reviews. Clinical oncology

Volumn 11, Issue 4, 2014, Pages 181-182

  Eggermont, Alexander M M ^a   Robert, Caroline ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; BRAF PROTEIN, HUMAN; CTLA4 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IPILIMUMAB; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MONOCLONAL ANTIBODY; NIVOLUMAB; PDCD1 PROTEIN, HUMAN; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN KINASE INHIBITOR; TUMOR PROTEIN;

CLINICAL TRIAL (TOPIC); DRUG ANTAGONISM; DRUG EFFECT; EXPERIMENTAL THERAPY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOTHERAPY; MELANOMA; METHODOLOGY; NOTE; T LYMPHOCYTE SUBPOPULATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; CTLA-4 ANTIGEN; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; MAP KINASE KINASE 1; MELANOMA; NEOPLASM PROTEINS; PROGRAMMED CELL DEATH 1 RECEPTOR; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; T-LYMPHOCYTE SUBSETS; THERAPIES, INVESTIGATIONAL;

EID: 84908127484     PISSN: None     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2014.36     Document Type: Note

References (0)